NCT02245620View on ClinicalTrials.gov

A Phase 2 Study to Evaluate the Impact of MTP-131 (Bendavia™) on Skeletal Muscle Function in Elderly

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

January 15, 2015

Primary Completion Date

July 6, 2016

Study Completion Date

July 6, 2016

Conditions
Skeletal Muscle Mitochondrial Dysfunction in the Elderly
Interventions
DRUG

Elamipretide

Elamipretide 0.25 mg/kg/hour administered as an intravenous infusion at the rate of 60 mL/hour for 2 hours

DRUG

Placebo

Placebo administered as intravenous infusion at a rate of 60 mL/hour for 2 hours

Trial Locations (1)

98104

The University of Washington Medical Center, Seattle

All Listed Sponsors
lead

Stealth BioTherapeutics Inc.

INDUSTRY

NCT02245620 - A Phase 2 Study to Evaluate the Impact of MTP-131 (Bendavia™) on Skeletal Muscle Function in Elderly | Biotech Hunter | Biotech Hunter